Volume 3, Issue 4 (Autumn 2017)                   Caspian J Neurol Sci 2017, 3(4): 231-240 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Etemadifar M, Fazli A. Myelin-Oligodendrocyte Glycoprotein Antibodies Spectrum Disorders. Caspian J Neurol Sci 2017; 3 (4) :231-240
URL: http://cjns.gums.ac.ir/article-1-206-en.html
Myelin-Oligodendrocyte Glycoprotein Antibodies Spectrum Disorders
Masoud Etemadifar1 , Ali Fazli * 2
1- Professor of Neurology, Department of Neurology, Isfahan University of Medical Science, Isfahan, Iran
2- Department of Neurology, Isfahan University of Medical Science, Isfahan, Iran; ali96fazli@yahoo.com
Abstract:   (3323 Views)
Myelin-Oligodendrocyte Glycoprotein (MOG) is an adhesive molecule responsible for myelin sheath structural integrity and maintenance. Patients with spectrum of inflammatory demyelinating disease particularly in central nervous system are reported to have antibodies against this protein. Diseases such as multiple sclerosis, clinically isolated syndrome, neuro-myelitis optica (NMO) spectrum disorders, acute disseminated encephalomyelitis, transverse myelitis and Optic neuritis seemed to have a correlation with anti-MOG antibodies. MRI findings of seropositive cases revealed spinal lesions, particularly in lower segments. For treatment of these patients methotrexate and azathioprine are suggested. Plasmaphresis and intravenous immunoglobulin may be useful too. However fingolimod and interferons can deteriorate the conditions. Finally it is concluded that anti-MOG antibodies can be a biomarker for CNS demyelinating disorders.
Keywords: Myelin-Oligodendrocyte Glycoprotein, Immunoglobulins, Myelitis, Transverse, Optic Neuritis
Full-Text [PDF 622 kb]   (1570 Downloads) |   |   Full-Text (HTML)  (1195 Views)  
Type of Study: Review | Subject: Special
Received: 2017/11/30 | Accepted: 2017/11/30 | Published: 2017/11/30
References
1. Roth M-P, Malfroy L, Offer C, Sevin J, Enault G, Borot N, et al. The Human Myelin Oligodendrocyte Glycoprotein (MOG) Gene: Complete Nucleotide Sequence and Structural Characterization. Genomics 1995;28(2):241-50. [DOI:10.1006/geno.1995.1137] [PMID]
2. Pham-Dinh D, Allinquant B, Ruberg M, Della Gaspera B, Nussbaum JL, Dautigny A. Characterization and Expression of the cDNA Coding for the Human Myelin/Oligodendrocyte Glycoprotein. ‎J Neurochem 1994;63(6):2353-6. [DOI:10.1046/j.1471-4159.1994.63062353.x] [PMID]
3. Pham-Dinh D, Mattei M-G, Nussbaum J-L, Roussel G, Pontarotti P, Roeckel N, et al. Myelin/Oligodendrocyte Glycoprotein Is a Member of a Subset of the Immunoglobulin Superfamily Encoded within the Major Histocompatibility Complex. Proc Natl Acad Sci U S A 1993;90(17):7990-4. [DOI:10.1073/pnas.90.17.7990] [PMID] [PMCID]
4. Boyle LH, Traherne JA, Plotnek G, Ward R, Trowsdale J. Splice Variation in the Cytoplasmic Domains of Myelin Oligodendrocyte Glycoprotein Affects Its Cellular Localisation and Transport1. J Neurochem 2007;102(6):1853-62. [DOI:10.1111/j.1471-4159.2007.04687.x] [PMID] [PMCID]
5. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al. Structural Insights into the Antigenicity of Myelin Oligodendrocyte Glycoprotein. Proc Natl Acad Sci U S A 2003;100(16):9446-51. [DOI:10.1073/pnas.1133443100] [PMID] [PMCID]
6. Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG, et al. The Crystal Structure of Myelin Oligodendrocyte Glycoprotein, a Key Autoantigen in Multiple Sclerosis. Proc Natl Acad Sci U S A 2003;100(19):11059-64. [DOI:10.1073/pnas.1833158100] [PMID] [PMCID]
7. Tsuburaya RS, Miki N, Tanaka K, Kageyama T, Irahara K, Mukaida S, et al. Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibodies in a Japanese Boy with Recurrent Optic Neuritis. Brain Dev 2015;37(1):145-8. [DOI:10.1016/j.braindev.2014.02.002] [PMID]
8. Ascherio A, Munger KL. Environmental Risk Factors for Multiple Sclerosis. Part I: the Role of Infection. Ann Neurol 2007;61(4):288-99. [DOI:10.1002/ana.21117] [PMID]
9. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and Anti-MBP Antibody Subclasses in Multiple Sclerosis. Mult Scler 2001;7(5):285-9. https://doi.org/10.1177/135245850100700503 [DOI:10.1191/135245801681137979] [PMID]
10. Xiao B-G, Linington C, Link Hd. Antibodies to Myelin-Oligodendrocyte Glycoprotein in Cerebrospinal Fluid from Patients with Multiple Sclerosis and Controls. J Neuroimmunol 1991;31(2):91-6. [DOI:10.1016/0165-5728(91)90014-X]
11. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, et al. Similar Low Frequency of anti-MOG IgG and IgM in MS Patients and Healthy Subjects. Neurology 2004;62(11):2092-4. [DOI:10.1212/01.WNL.0000127615.15768.AE] [PMID]
12. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 Other Anti-glial and Anti-neuronal Autoantibodies in 'Pattern II Multiple Sclerosis' and Brain Biopsy Findings in a MOG-IgG-positive Case. Mult Scler 2016;1541-9. [DOI:10.1177/1352458515622986] [PMID]
13. Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, et al. Temporal Dynamics of anti-MOG Antibodies in CNS Demyelinating Diseases. Clin Immunol 2011;138(3):247-54. [DOI:10.1016/j.clim.2010.11.013] [PMID]
14. Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis Optica: a Positive Appraisal of Seronegative Cases. Eur J Neurol 2015;22(12):1511-8, e82-3.
15. Lucchinetti CF, Guo Y, Popescu BFG, Fujihara K, Itoyama Y, Misu T. The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica. Brain Pathol 2014;24(1):83-97. [DOI:10.1111/bpa.12099] [PMID] [PMCID]
16. Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, et al. Severe Demyelination but no Astrocytopathy in Clinically Definite Neuromyelitis Optica with Anti-Myelin-Oligodendrocyte Glycoprotein Antibody. Mult Scler 2015;21(5):656-9. [DOI:10.1177/1352458514551455] [PMID]
17. Pröbstel A-K, Rudolf G, Dornmair K, Collongues N, Chanson J-B, Sanderson NS, et al. Anti-MOG Antibodies Are Present in a Subgroup of Patients with a Neuromyelitis Optica Phenotype. J Neuroinflammation 2015;12(1):1. [DOI:10.1186/s12974-015-0256-1]
18. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG Antibody-Positive and AQP4 Antibody-Positive NMO Spectrum Disorders. Neurology 2014;82(6):474-81. [DOI:10.1212/WNL.0000000000000101] [PMID] [PMCID]
19. Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, et al. Antibodies to MOG and AQP4 in Children with Neuromyelitis Optica and Limited Forms of the Disease. J Neurol Neurosurg Psychiatry 2016; 87(8):897-905. [DOI:10.1136/jnnp-2015-311743] [PMID]
20. Dale RC. Acute Disseminated Encephalomyelitis. Semin Pediatr Infect Dis 2003;14(2):90-5. [DOI:10.1053/spid.2003.127225] [PMID]
21. Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-Vaccination Encephalomyelitis: Literature Review and Illustrative Case. J Clin Neurosci 2008;15(12):1315-22. [DOI:10.1016/j.jocn.2008.05.002] [PMID]
22. Baumann M, Hennes E, Schanda K, Karenfort M, Bajer-Kornek B, Diepold K, et al. OP65–3006: Clinical Characteristics and Neuroradiological Findings in Children with Multiphasic Demyelinating Encephalomyelitis and MOG Antibodies. Eur J Paediatr Neurol 2015;19:S21. [DOI:10.1016/S1090-3798(15)30066-0]
23. Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, et al. Fulminant Demyelinating Encephalomyelitis Insights from Antibody Studies and Neuropathology. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e175. [DOI:10.1212/NXI.0000000000000175] [PMID] [PMCID]
24. Numa S, Kasai T, Kondo T, Kushimura Y, Kimura A, Takahashi H, et al. An Adult Case of Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Multiphasic Acute Disseminated Encephalomyelitis at 33-year Intervals. Intern Med 2016;55(6):699-702. [DOI:10.2169/internalmedicine.55.5727] [PMID]
25. Miyauchi A, Monden Y, Watanabe M, Sugie H, Morita M, Kezuka T, et al. Persistent Presence of the Anti-Myelin Oligodendrocyte Glycoprotein Autoantibody in a Pediatric Case of Acute Disseminated EncephalomyElitis Followed by Optic Neuritis. Neuropediatrics 2014;45(3):196-9. https://doi.org/10.1055/s-0034-1371179 [DOI:10.1055/s-0034-1372693] [PMID]
26. Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, et al. Differentiating Neuromyelitis Optica from Other Causes of Longitudinally Extensive Transverse Myelitis on Spinal Magnetic Resonance Imaging. Mult Scler 2016;22(3):302-11. [DOI:10.1177/1352458515591069] [PMID] [PMCID]
27. Cobo-Calvo A, Sepulveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martinez-Yelamos S, et al. Antibodies to Myelin Oligodendrocyte Glycoprotein in Aquaporin 4 Antibody Seronegative Longitudinally Extensive Transverse Myelitis: Clinical and Prognostic Implications. Mult Scler 2016;22(3):312-9. [DOI:10.1177/1352458515591071] [PMID]
28. Amano H, Miyamoto N, Shimura H, Sato DK, Fujihara K, Ueno S, et al. Influenza-associated MOG Antibody-Positive Longitudinally Extensive Transverse Myelitis: A Case Report. BMC Neurol 2014;14:224. [DOI:10.1186/s12883-014-0224-x] [PMID] [PMCID]
29. Chalmoukou K, Stathopoulos P, Alexopoulos H, Akrivou S, Dalakas M. Recurrent Optic Neuritis (rON) Is Characterised by Anti-MOG Antibodies: A Follow-up Study (P5. 274). Neurology 2015;84(14 Supplement):P5. 274.
30. Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-Antibody and Anti–MOG Antibody in Optic Neuritis. J Neuroophthalmol 2012;32(2):107-10. [DOI:10.1097/WNO.0b013e31823c9b6c] [PMID]
31. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti–myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients with Optic Neuritis. Arch Neurol 2012;69(6):752-6. [DOI:10.1001/archneurol.2011.2956] [PMID]
32. Huppke P, Rostasy K, Karenfort M, Huppke B, Seidl R, Leiz S, et al. Acute Disseminated Encephalomyelitis Followed by Recurrent or Monophasic Optic Neuritis in Pediatric Patients. Mult Scler 2013;19(7):941-6. [DOI:10.1177/1352458512466317] [PMID]
33. Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to Myelin Oligodendrocyte Glycoprotein in Bilateral and Recurrent Optic Neuritis. Neurol Neuroimmunol Neuroinflamm 2014;1(4):e40. [DOI:10.1212/NXI.0000000000000040] [PMID] [PMCID]
34. Tsuburaya RS, Miki N, Tanaka K, Kageyama T, Irahara K, Mukaida S, et al. Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibodies in a Japanese Boy with Recurrent Optic Neuritis. Brain Dev 2015;37(1):145-8. [DOI:10.1016/j.braindev.2014.02.002] [PMID]
35. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al. Antibodies Against the Myelin Oligodendrocyte Glycoprotein and the Myelin Basic Protein in Multiple Sclerosis and Other Neurological Diseases: A Comparative Study. Brain 1999;122 (Pt 11):2047-56. [DOI:10.1093/brain/122.11.2047] [PMID]
36. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement Activating Antibodies to Myelin Oligodendrocyte Glycoprotein in Neuromyelitis Optica and Related Disorders. J Neuroinflammation 2011; 8:184. [DOI:10.1186/1742-2094-8-184] [PMID] [PMCID]
37. Kovacs KT, Kalluri SR, Boza-Serrano A, Deierborg T, Csepany T, Simo M, et al. Change in Autoantibody and Cytokine Responses During the Evolution of Neuromyelitis Optica in Patients with Systemic Lupus Erythematosus: A Preliminary Study. Mult Scler 2016;22(9):1192-201. [DOI:10.1177/1352458515613165] [PMID]
38. Oshiro A, Nakamura S, Tamashiro K, Fujihara K. Anti-MOG + Neuromyelitis Optica Spectrum Disorders Treated with Plasmapheresis. No To Hattatsu 2016;48(3):199-203. [Text in Japanese] [PMID]
39. Miyazaki T, Nakajima H, Motomura M, Tanaka K, Maeda Y, Shiraishi H, et al. A Case of Recurrent Optic Neuritis Associated with Cerebral and Spinal Cord Lesions and Autoantibodies Against Myelin Oligodendrocyte Glycoprotein Relapsed after Fingolimod Therapy. Rinsho Shinkeigaku 2016;56(4):265-9. [DOI:10.5692/clinicalneurol.cn-000756] [PMID]
40. Thulasirajah S, Pohl D, Davila-Acosta J, Venkateswaran S. Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy. Neuropediatrics 2016; 47(4):245-52. [DOI:10.1055/s-0036-1583184] [PMID]
41. Hacohen Y, Absoud M, Gadian J, Clarke A, Hemingway C, Palace J, et al. PP08.4 – 2929:Relapsing Central Nervous System Demyelination in Children with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies. Eur J Paediatr Neurol 2015;19(supplement 1):S61. [DOI:10.1016/S1090-3798(15)30200-2]
42. Ram D, Hughes M. PP08. 6–2786: Relapsing MOG Antibody Associated Encephalomyelitis: A Case Report. Eur J Paediatr Neurol 2015;19:S61. [DOI:10.1016/S1090-3798(15)30202-6]
43. Brilot F, Dale RC, Selter RC, Grummel V, Reddy Kalluri S, Aslam M, et al. Antibodies to Native Myelin Oligodendrocyte Glycoprotein in Children with Inflammatory Demyelinating Central Nervous System Disease. Ann Neurol 2009;66(6):833-42. [DOI:10.1002/ana.21916] [PMID]
44. Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a Distinct Subgroup of Adult Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3(5):e257. [DOI:10.1212/NXI.0000000000000257] [PMID] [PMCID]
45. Kong XY, Peng JT, Liu LJ, Yan R, Zhang XJ. Anti-MOG antibody in different types of immune-mediated optic neuritis. Zhonghua Yan Ke Za Zhi 2012;48(12):1069-72. [Text in Chinese] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb